Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 2/20 | 0.43 |
| ▸ | GUCY1A2 | P33402 | 2/20 | 0.43 |
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.43 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17717782 | 0.89 | GUCY1B2 (0.44) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15664968 | 0.84 | GUCY1B2 (0.50) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17224622 | 0.82 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15664743 | 0.81 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| Trifluoroacetic Acid SCHEMBL16402979 | 0.81 | GUCY1B2 (0.48) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17803149 | 0.76 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15707621 | 0.74 | PTGS1 (0.38) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16403535 | 0.74 | GUCY1B2 (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17229123 | 0.73 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL15705453 | 0.73 | GUCY1B2 (0.51) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| EP-3227287-B1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma AG (DE) | 2019-08-07 | — | — | EP | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-21 | — | — | US | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-26 | — | — | US | disclosed |
| EP-3227287-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016087343-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016087343-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304278-A1 | HETEROARYL-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINES AND THEIR USE | TNNI3, CYP11B2, PPIP5K2 | GUCY1B2 1819/4885GUCY1A2 876/4885GUCY1A1 1463/4885 |
| US-10292970-B2 | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use | TNNI3, CYP11B2, PPIP5K2 | GUCY1B2 1819/4885GUCY1A2 876/4885GUCY1A1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.